The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: Results of a prospective study

被引:12
|
作者
Shim, Ji Sung [1 ]
Choi, Hoon [1 ]
Noh, Tae Il [1 ]
Tae, Jong Hyun [2 ]
Yoon, Sung Goo [2 ]
Kang, Seok Ho [2 ,3 ]
Bae, Jae Hyun [1 ,3 ]
Park, Hong Seok [3 ,4 ]
Park, Jae Young [1 ,3 ]
机构
[1] Korea Univ, Ansan Hosp, Dept Urol, Ansan 425707, South Korea
[2] Korea Univ, Anam Hosp, Dept Urol, Seoul, South Korea
[3] Korea Univ, Coll Med, Dept Urol, Seoul 136705, South Korea
[4] Korea Univ, Guro Hosp, Dept Urol, Seoul, South Korea
关键词
Neoplasm invasiveness; Recurrence; Urinary bladder neoplasms;
D O I
10.4111/kju.2015.56.6.429
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: This study was designed to estimate the value of a second transurethral resection of bladder tumor (TURBT) procedure in patients with initially diagnosed T1 high-grade bladder cancer. Materials and Methods: Between August 2009 and January 2013, a total of 29 patients with T1 high-grade bladder cancer prospectively underwent a second TURBT procedure. Evaluation included the presence of previously undetected residual tumor, changes to histopathological staging or grading, and tumor location. Recurrence-free and progression-free survival curves were generated to compare the prognosis between the groups with and without residual lesions by use of the Kaplan-Meier method. Results: Of 29 patients, 22 patients (75.9%) had residual disease after the second TURBT. Staging was as follows: no tumor, 7 (24.1%); Ta, 5 (17.2%); T1, 6 (20.7%); Tis, 6 (20.7%); Ta+Tis, 1 (3.4%); T1+Tis, 1 (3.4%); and >= T2, 3 (10.3%). The muscle layer was included in the surgical specimen after the initial TURBT in 24 patients (82.7%). In three patients whose cancer was upstaged to pT2 after the second TURBT, the initial surgical specimen contained the muscle layer. In the group with residual lesions, the 3-year recurrence-free survival and 3-year progression-free survival rates were 50% and 66.9%, respectively, whereas these rates were 68.6% and 68.6%, respectively, in the group without residual lesions. This difference was not statistically significant. Conclusions: Initial TURBT does not seem to be enough to control T1 high-grade bladder cancer. Therefore, a routine second TURBT procedure should be recommended in patients with T1 high-grade bladder cancer to accomplish adequate tumor resection and to identify patients who may need to undergo prompt cystectomy.
引用
收藏
页码:429 / 434
页数:6
相关论文
共 50 条
  • [21] Predicting residual tumor for T1 high-grade bladder urothelial carcinoma before second transurethral resection specimens.
    Takeuchi, Ario
    Shiota, Masaki
    Inokuchi, Junichi
    Eto, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?
    Shariat, Shahrokh
    Gontero, Paolo
    Catto, James W. F.
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (04): : 663 - 669
  • [23] A Restaging Transurethral Resection of Bladder Tumor Is Always Necessary For High-grade T1 Non-muscle-invasive Bladder Cancer
    Lichtbroun, Benjamin
    Srivastava, Arnav
    Ghodoussipour, Saum
    EUROPEAN UROLOGY FOCUS, 2023, 9 (04): : 557 - 558
  • [24] A Restaging Transurethral Resection of the Bladder Is Always Necessary for High-grade T1 Non-muscle-invasive Bladder Cancer: Con
    Gontero, Paolo
    Livoti, Simone
    Soria, Francesco
    EUROPEAN UROLOGY FOCUS, 2023, 9 (04): : 559 - 560
  • [25] Radiotherapy for High-grade T1 Bladder Cancer
    Raby, Sophie E. M.
    Choudhury, Ananya
    EUROPEAN UROLOGY FOCUS, 2018, 4 (04): : 506 - 508
  • [26] High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study
    Ferro, Matteo
    Vartolomei, Mihai Dorin
    Cantiello, Francesco
    Lucarelli, Giuseppe
    Di Stasi, Savino M.
    Hurle, Rodolfo
    Guazzoni, Giorgio
    Busetto, Gian Maria
    De Berardinis, Ettore
    Damiano, Rocco
    Perdona, Sisto
    Borghesi, Marco
    Schiavina, Riccardo
    Almeida, Gilberto L.
    Bove, Pierluigi
    Lima, Estevao
    Grimaldi, Giovanni
    Autorino, Riccardo
    Crisan, Nicolae
    Abu Farhan, Abdal Rahman
    Verze, Paolo
    Battaglia, Michele
    Serretta, Vincenzo
    Russo, Giorgio Ivan
    Morgia, Giuseppe
    Musi, Gennaro
    de Cobelli, Ottavio
    Mirone, Vincenzo
    Shariat, Shahrokh F.
    UROLOGIA INTERNATIONALIS, 2018, 101 (01) : 7 - 15
  • [27] Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette–Guerin
    Beppe Calò
    Ugo Falagario
    Francesca Sanguedolce
    Alessandro Veccia
    Marco Chirico
    Emanuel Carvalho-Diaz
    Paulo Mota
    Estêvão Lima
    Riccardo Autorino
    Giuseppe Carrieri
    Luigi Cormio
    World Journal of Urology, 2020, 38 : 3161 - 3167
  • [28] Effect of Intravesical Bacilli Calmette-Guerin Therapy After Second Transurethral Resection in Stage Ta T1 High-Grade Bladder Cancer
    Kimura, Yusuke
    Honda, Masashi
    Morizane, Shuichi
    Hikita, Katsuya
    Isoyama, Tadahiro
    Ono, Koji
    Koumi, Tsutomu
    Takahashi, Chihiro
    Takenaka, Atsushi
    YONAGO ACTA MEDICA, 2019, 62 (02) : 191 - 197
  • [29] Impact of second transurethral resection on recurrence in patients with high-grade Ta bladder cancer
    Taoka, Rikiya
    Matsuoka, Yuki
    Kohashiguchi, Kana
    Miura, Takayoshi
    Tohi, Yoichiro
    Miyauchi, Yasuyuki
    Kato, Takuma
    Tsunemori, Hiroyuki
    Ueda, Nobufumi
    Kakehi, Yoshiyuki
    Sugimoto, Mikio
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (12) : 1130 - 1135
  • [30] Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer
    Ferro, Matteo
    Di Lorenzo, Giuseppe
    Buonerba, Carlo
    Lucarelli, Giuseppe
    Russo, Giorgio Ivan
    Cantiello, Francesco
    Abu Farhan, Abdal Rahman
    Di Stasi, Savino
    Musi, Gennaro
    Hurle, Rodolfo
    Vincenzo, Serretta
    Busetto, Gian Maria
    De Berardinis, Ettore
    Perdona, Sisto
    Borghesi, Marco
    Schiavina, Riccardo
    Almeida, Gilberto L.
    Bove, Pierluigi
    Lima, Estevao
    Grimaldi, Giovanni
    Matei, Deliu Victor
    Mistretta, Francesco Alessandro
    Crisan, Nicolae
    Terracciano, Daniela
    Paolo, Verze
    Battaglia, Michele
    Guazzoni, Giorgio
    Autorino, Riccardo
    Morgia, Giuseppe
    Damiano, Rocco
    Muto, Matteo
    La Rocca, Roberto
    Mirone, Vincenzo
    de Cobelli, Ottavio
    Vartolomei, Mihai Dorin
    JOURNAL OF CANCER, 2018, 9 (22): : 4250 - 4254